Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Device Safety topic
No spam. Unsubscribe anytime.
Committee adopts amendment to phase out DEHP in IV bags and tubing; sponsor cites health concerns
Summary
The committee adopted an amendment to House Bill 26‑14, which would prohibit DEHP in IV bags and tubing and set phase‑out deadlines; sponsor Rep Kosarowski and members cited evidence of DEHP leaching and toxicity. The amendment revises notification/deadline timing; the transcript records the amendment’s adoption but does not include a final committee roll call on the bill in this excerpt.
House Bill 26‑14, as explained to the committee, would prohibit the use of di‑2‑ethylhexyl phthalate (DEHP) in intravenous bags and tubing, citing concerns that DEHP can leach from PVC medical devices into administered fluids. The bill sets phase‑out deadlines for manufacturers (bags by 2030, tubing by 2035) and allows limited extensions; amendment A03676 revised the timing for when manufacturers must notify customers if they will seek an extension.
Erica summarized the measure and the amendment, noting companies can seek a two‑year extension for IV container bags; sponsor Rep Kosarowski said research links DEHP to health risks and described the irony of administering chemotherapy through tubing that may leach harmful plasticizers.
Members told the committee they had met with stakeholders and that the transition is already underway for many manufacturers; one member said the change should not increase costs. Committee members voiced support and adopted the amendment. The transcript records adoption of the amendment but does not show a final roll‑call on the underlying bill in the excerpt.
Next steps: Amendment A03676 was adopted; the bill’s final committee disposition is not specified in the provided transcript.
